Can a common anti-inflammatory cut opioid use after spinal fusion?
NCT ID NCT06513208
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the anti-inflammatory drug ketorolac can lower the amount of strong painkillers (opioids) needed after lumbar spinal fusion surgery. About 140 adults having one- or two-level fusion will receive either ketorolac or a placebo for the first 48 hours after surgery. The goal is to see if ketorolac helps control pain without harming bone healing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUMBAR SPINAL STENOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Maryland St. Joseph Medical Center
RECRUITINGTowson, Maryland, 21204, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••